 | Up a level |
Ghielmini, M.; Rufibach, K.; Salles, G.; Leoncini-Franscini, L.; Léger-Falandry, C.; Cogliatti, S.; Fey, M.; Martinelli, G.; Stahel, R.; Lohri, A.; Ketterer, N.; Wernli, M.; Cerny, T.; Hsu Schmitz, S.-F. (2005). Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology, 16(10), pp. 1675-1682. Oxford University Press 10.1093/annonc/mdi320
Zolitschka, B.; Schaebitz, F.; Luecke, A.; Willle, M.; Mayr, C.; Ohlendorf, C.; Anselmetti, Flavio; Ariztegui, D.; Corbella, H.; Ercolano, B.; Fey, M.; Haberzettl, T.; Maidana, N.; Oliva, G.E.; Paez, M.; Schleser, G.H. (2004). Climate Changes in Southern Patagonia (Santa Cruz, Argentina) Inferred From Lake Sediments: The Multi-Proxy Approach of SALSA. PAGES news, 12, pp. 9-11. Pages International Project Office
Thürlimann, B.; Beretta, K.; Bacchi, M.; Castiglione-Gertsch, M.; Goldhirsch, A.; Jungi, W. F.; Cavalli, F.; Senn, H.-J.; Fey, M.; Löhnert, T. (1996). First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of oncology, 7(5), pp. 471-479. Oxford University Press 10.1093/oxfordjournals.annonc.a010635
